Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: Focus on challenging populations

Research output: Contribution to journalReview articlepeer-review

Abstract

In recent years, immune-checkpoint inhibitors (ICIs) have represented one of the major breakthroughs in advanced non-small cell lung cancer treatment scenario. However, enrollment in registering clinical trials is usually restricted, since frail patients (i.e., elderly, individuals with poor performance status and/or active brain metastases), as well as patients with chronic infections or who take concurrent medications, such as steroids, are routinely excluded. Thus, safety and efficacy of ICIs for these subgroups have not been adequately assessed in clinical trials, although these populations often occur in clinical practice. We reviewed the available data regarding the use of ICIs in these ‘special' populations, including a focus on the issues raised by the administration of immunotherapy in lung cancer patients infected with Sars-Cov-2.

Original languageEnglish
Pages (from-to)509-525
Number of pages17
JournalImmunotherapy
Volume13
Issue number6
DOIs
Publication statusPublished - Apr 2021

Keywords

  • chronic viral infections
  • concomitant medications
  • covid-19
  • frail patients
  • immune-checkpoint inhibitors
  • immunotherapy
  • lung cancer
  • special populations

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: Focus on challenging populations'. Together they form a unique fingerprint.

Cite this